CN Patent

CN115385899B — ROCK2抑制剂belumosudil的氘代药物及用途

Assigned to Yaokang Zhongtuo Jiangsu Pharmaceutical Technology Co ltd · Expires 2024-04-02 · 2y expired

What this patent protects

本发明公开了ROCK2抑制剂belumosudil的氘代化合物及其药学上可接受的盐，如下式Ⅰ所示，本发明所述的ROCK2抑制剂belumosudil的氘代药物，能进一步降低belumosudil的给药剂量和可能的毒副作用，改善了药代动力学性质。

USPTO Abstract

本发明公开了ROCK2抑制剂belumosudil的氘代化合物及其药学上可接受的盐，如下式Ⅰ所示，本发明所述的ROCK2抑制剂belumosudil的氘代药物，能进一步降低belumosudil的给药剂量和可能的毒副作用，改善了药代动力学性质。

Drugs covered by this patent

Patent Metadata

Patent number
CN115385899B
Jurisdiction
CN
Classification
—
Expires
2024-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Yaokang Zhongtuo Jiangsu Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.